Skip to content

Checked

Class IIDrug recallOngoing

Ondansetron ODT Tablets recall

Recalled by Preferred Pharmaceuticals, Inc. of Anaheim, CA · FDA report 12/24/2025

Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.

Class
Class II
Moderate
Status
Ongoing
Recall started
11/17/2025
Distribution
See below

Reason for recall

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Class II: Use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.

Recalled product

Product
Ondansetron ODT Tablets, USP 4mg, 1x10 unit dose tablets, Mfg: Glenmark Pharmaceuticals Limited, Repackaged by Preferred Pharmaceuticals NDC 68788-8666-01
Lot and code info
Lot: J1325J, I1725P, EXP Date: 4/30/2027.
Quantity
575 1x10 Foil Blister Packs
Recall number
D-0239-2026
Event ID
98141
Initiated by
Voluntary: Firm initiated

Where it was distributed

Natinowide in the USA

Recall timeline

  1. 11/17/2025Firm started the recall
  2. 12/17/2025FDA classified it as Class II
  3. 12/24/2025Published in the FDA enforcement report

More recalls from Preferred Pharmaceuticals

Frequently asked questions

Why was Ondansetron ODT Tablets recalled?
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
What does Class II mean?
Class II is FDA's moderate recall category: use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
Is this recall still active?
The FDA lists the recall as ongoing. The recall is still in progress.

Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 12/24/2025 · Do not rely on openFDA to make decisions regarding medical care